Sorry, you need to enable JavaScript to visit this website.

DEPO-subQ PROVERA 104® (medroxyprogesterone acetate) Highlights


These highlights do not include all the information needed to use DEPO-SUBQ PROVERA 104® safely and effectively. See full prescribing information for DEPO-SUBQ PROVERA 104.

DEPO-SUBQ PROVERA 104 (medroxyprogesterone acetate) injectable suspension, for subcutaneous use
Initial U.S. Approval: 1959


See full prescribing information for complete boxed warning.

  • Women who use depo-subQ provera 104 may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible. (5.1)
  • It is unknown if use of depo-subQ provera 104 during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life. (5.1)
  • Depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate. (1, 5.1)


Depo-subQ provera 104 is a progestin that is indicated in females of reproductive age for:

  • Prevention of pregnancy. (1)
  • Management of endometriosis-associated pain. (1)

Limitations of Use:

Use of depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate. (1, 5.1)


  • Only for healthcare professional administration. (2.1)
  • Prior to first injection confirm the patient is not pregnant. (2.1)
  • Administer 104 mg of depo-subQ provera 104 by subcutaneous injection into the anterior thigh or abdomen, once every 12 to 14 weeks. (2.1)
  • See Full Prescribing Information for recommendations on switching from another contraceptive method to depo-subQ provera 104. (2.2)
  • See Full Prescribing Information for important preparation and administration instructions. (2.3)


Injectable suspension: 104 mg/0.65 mL (3)


  • Active thrombophlebitis, or current or history of thromboembolic disorders, or cerebral vascular disease. (4)
  • Known, suspected, or past malignancy of the breast. (4)
  • Significant liver disease. (4)
  • Known hypersensitivity to medroxyprogesterone acetate or any of the ingredients of depo-subQ provera 104. (4)
  • Undiagnosed vaginal bleeding. (4)


  • Thromboembolic disorders: Discontinue depo-subQ provera 104 in patients who develop arterial or venous thrombosis. (5.2)
  • Breast cancer risks: Monitor women with a family history of breast cancer or a significant risk of breast cancer carefully. (5.3)
  • Ectopic pregnancy: Consider ectopic pregnancy if a woman becomes pregnant or complains of severe abdominal pain. (5.4)
  • Anaphylaxis: Provide emergency medical treatment. (5.5)
  • Injection site reactions (e.g., persistent atrophy, dimpling/indentation, and lump/nodule) have been reported. (5.10)
  • Diabetics may be at greater risk of hyperglycemia. (5.12)
  • Jaundice and elevated transaminase: Discontinue depo-subQ provera 104 if jaundice or elevated transaminase levels develop. (5.13)


Most common adverse reactions (incidence >5%) are dysfunctional uterine bleeding, headache, increased weight, amenorrhea, and injection site reactions. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or


Strong CYP3A inhibitors and inducers: Avoid concomitant use. (7)


  • Nursing mothers: Detectable amounts of drug have been identified in the milk of mothers receiving depot-medroxyprogesterone acetate. (8.3)
  • Pediatric patients (after menarche): Bone loss is a particular concern. (8.4)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 12/2019

What's New

No Current Announcements.

Therapeutic Area

Contact Pfizer Medical

Report an Adverse Event


Please enter your search term(s) for DEPO-SUBQ PROVERA 104®

Contact Pfizer

Need to report an Adverse Event, Side Effect or Product Quality Concern?

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or

Have a Medical Question on a Pfizer Prescription Medicine?
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
Have a Question about Pfizer Clinical Trials?
If you are looking for information about Pfizer studies currently recruiting new patients in your area, you can begin your search on our website. For questions about a Pfizer Clinical Trial, call (800) 718-1021 or email [email protected]
Need Information on Pfizer’s Patient Assistance Programs?

Pfizer RxPathways® connects eligible patients, regardless of their insurance status, to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. For more information, please call (844) 989-7284 or visit

Eligible patients can register for valuable savings offers for nearly 40 brand name medications. Visit for more information.